论文部分内容阅读
目的评价羟苯磺酸钙治疗糖尿病肾病的临床疗效及安全性。方法将90例糖尿病肾病患者随机分为对照组45例和试验组45例。对照组予以优质低蛋白饮食、适度运动、口服降糖药物和/或皮下注射胰岛素等综合治疗;试验组在对照组的基础上,予以口服羟苯磺酸钙每次0.5 g,每日3次。2组患者均治疗12周。比较2组患者治疗前后尿白蛋白排泄率、24 h尿蛋白定量、血清肌酸酐和尿素氮等指标以及不良反应发生率有无差异。结果治疗后,试验组的有效率为86.67%显著高于对照组62.22%(P<0.05)。治疗后,试验组尿白蛋白排泄率、24 h尿蛋白定量、血清肌酸酐和尿素氮较治疗前明显下降(P<0.05),且试验组明显优于对照组(P<0.05)。治疗期间,试验组出现2例与药物有关的不良反应,对照组未发生不良反应。结论羟苯磺酸钙治疗糖尿病肾病的临床疗效确切,且无明显药物不良反应,值得在临床上推广。
Objective To evaluate the clinical efficacy and safety of calcium dobesilate in the treatment of diabetic nephropathy. Methods Ninety patients with diabetic nephropathy were randomly divided into control group (n = 45) and experimental group (n = 45). The control group was given high-quality low-protein diet, moderate exercise, oral hypoglycemic drugs and / or subcutaneous injection of insulin and other comprehensive treatment; the experimental group in the control group, based on the oral calcium dobesilate 0.5 g, 3 times a day . Two groups of patients were treated for 12 weeks. Urinary albumin excretion rate, 24 h urinary protein excretion, serum creatinine and urea nitrogen and other indicators of adverse reactions were compared between two groups before and after treatment. Results After treatment, the effective rate of the experimental group was 86.67%, significantly higher than that of the control group (62.22%, P <0.05). After treatment, the urinary albumin excretion rate, 24 h urinary protein excretion, serum creatinine and urea nitrogen in the experimental group were significantly lower than those before treatment (P <0.05), and the experimental group was significantly better than the control group (P <0.05). During the treatment, there were 2 adverse drug reactions in the test group and no adverse reactions in the control group. Conclusion Calcium dobesilate in the treatment of diabetic nephropathy is clinically effective and has no obvious side effects. It is worth to be popularized clinically.